Endurant Capital Management LP acquired a new position in Oncomed Pharmaceuticals Inc (NASDAQ:OMED) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 139,100 shares of the biopharmaceutical company’s stock, valued at approximately $570,000. Endurant Capital Management LP owned approximately 0.37% of Oncomed Pharmaceuticals as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. BlueCrest Capital Management Ltd acquired a new stake in Oncomed Pharmaceuticals during the 4th quarter valued at $133,000. Paloma Partners Management Co acquired a new stake in Oncomed Pharmaceuticals during the 4th quarter valued at $135,000. Virtu Financial LLC acquired a new stake in Oncomed Pharmaceuticals during the 4th quarter valued at $170,000. Goldman Sachs Group Inc. grew its holdings in Oncomed Pharmaceuticals by 89.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 52,106 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 24,653 shares in the last quarter. Finally, Spark Investment Management LLC acquired a new stake in Oncomed Pharmaceuticals during the 4th quarter valued at $228,000. 53.47% of the stock is owned by institutional investors.
Shares of Oncomed Pharmaceuticals Inc (NASDAQ OMED) opened at $2.93 on Tuesday. Oncomed Pharmaceuticals Inc has a fifty-two week low of $1.74 and a fifty-two week high of $10.00.
Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.59. The company had revenue of $20.64 million for the quarter, compared to the consensus estimate of $5.10 million. analysts expect that Oncomed Pharmaceuticals Inc will post -1.04 earnings per share for the current year.
A number of research firms recently weighed in on OMED. Cantor Fitzgerald set a $6.00 price target on shares of Oncomed Pharmaceuticals and gave the company a “hold” rating in a report on Thursday, January 4th. Zacks Investment Research raised shares of Oncomed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 price target for the company in a report on Thursday, January 4th. Finally, HC Wainwright reaffirmed a “hold” rating and set a $3.00 price target on shares of Oncomed Pharmaceuticals in a report on Friday, March 9th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $5.31.
TRADEMARK VIOLATION WARNING: This piece was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://ledgergazette.com/2018/03/20/endurant-capital-management-lp-acquires-new-stake-in-oncomed-pharmaceuticals-inc-omed.html.
Oncomed Pharmaceuticals Profile
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer’s growth, resistance, recurrence and metastasis. The Company’s therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11).
Want to see what other hedge funds are holding OMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oncomed Pharmaceuticals Inc (NASDAQ:OMED).
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.